



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

N-Bromoacetyl- β -alanine

Cat. No.:	HY-141379
CAS No.:	89520-11-6
Molecular Formula:	C ₅ H ₈ BrNO ₂
Molecular Weight:	210.03
Target:	PROTAC Linkers; ADC Linker
Pathway:	PROTAC; Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (297.58 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	4.7612 mL	23.8061 mL	47.6122 mL
		5 mM	0.9522 mL	4.7612 mL	9.5224 mL
	10 mM	0.4761 mL	2.3806 mL	4.7612 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.08 mg/mL (9.90 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 2.08 mg/mL (9.90 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: \geq 2.08 mg/mL (9.90 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	N-Bromoacetyl- β -alanine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs ^[1] . N-Bromoacetyl- β -alanine is also a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) ^[2] .	
IC ₅₀ & Target	Alkyl-Chain	Cleavable
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

- [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. *EBioMedicine*. 2018 Oct;36:553-562.
- [2]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov*. 2017 May;16(5):315-337.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA